BIOMARIN PHARMACEUTICAL INC Deferred Income Tax Assets, Net
BIOMARIN PHARMACEUTICAL INC (BMRN) had Deferred Income Tax Assets, Net of $888.58 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Assets, Net $888.58M.
- 2026-03-31: Deferred Income Tax Assets, Net $1.50B.
- 2025-12-31: Deferred Income Tax Assets, Net $1.51B.
- 2025-09-30: Deferred Income Tax Assets, Net $1.51B.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $888.58M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.50B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.51B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.51B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $1.43B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.46B 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $1.49B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.53B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.55B 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $1.55B 10-Q · filed 2024-04-26 | |
| 2023-12-31 | $1.55B 10-K · filed 2025-02-24 | |
| 2023-09-30 | $1.52B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.51B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $1.51B 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $1.51B 10-K · filed 2024-02-26 | |
| 2022-09-30 | $1.46B 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $1.45B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.45B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $1.45B 10-K · filed 2023-02-27 | $1.45B 10-K · filed 2022-02-25 |
| 2021-09-30 | $1.45B 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $1.43B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $1.43B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $1.43B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $1.40B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $555.14M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $539.99M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $549.42M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $525.13M 10-Q/A · filed 2019-11-04 | |
| 2018-12-31 | $460.95M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |